Clinical trial
Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete…
NCT00362674 · Bukwang Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00362674 |
|---|---|
| Title | Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial |
| Official title | An Open-label, Observation Study to Evaluate the Durability of Antiviral Activity in Chronic Hepatitis B Patients Who Showed Complete Response in L-FMAU-301,L-FMAU-302 or L-FMAU-303 Trial |
| Lead sponsor | Bukwang Pharmaceutical, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Hepatitis B |
| Start date | Jun 1, 2005 |
| First posted | Aug 10, 2006 |
| Last update posted | Feb 1, 2017 |
| Countries | South Korea |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: